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Abstract 
Background: Nuclear receptor family member, Estrogen related receptor β, and the Hedgehog signal transduction 
pathway are both reported to relate to tumorigenesis and induced pluripotent stem cell reprogramming. We hypoth-
esize that Estrogen related receptor β can modulate the Hedgehog signaling pathway and affect Hedgehog driven 
downstream gene expression.
Results: We established an estrogen related receptor β-expressing Hedgehog-responsive NIH3T3 cell line by Esrrb 
transfection, and performed mRNA profiling using RNA-Seq after Hedgehog ligand conditioned medium treatment. 
Esrrb expression altered 171 genes, while Hedgehog signaling activation alone altered 339 genes. Additionally, estro-
gen related receptor β expression in combination with Hedgehog signaling activation affects a group of 109 Hedge-
hog responsive mRNAs, including Hsd11b1, Ogn, Smoc2, Igf1, Pdcd4, Igfbp4, Stmn1, Hp, Hoxd8, Top2a, Tubb4b, Sfrp2, 
Saa3, Prl2c3 and Dpt.
Conclusions: We conclude that Estrogen related receptor β is capable of interacting with Hh-signaling downstream 
targets. Our results suggest a new level of regulation of Hedgehog signaling by Estrogen related receptor β, and 
indicate modulation of Estrogen related receptor β can be a new strategy to regulate various functions driven by the 
Hedgehog signaling pathway.
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Background
Hedgehog (Hh) signaling is a pivotal signaling pathway 
in embryonic pattern formation, stem cell/cancer stem 
cell self-renewal, as well as induced pluripotent stem cells 
induction [1–12]. An early study showed the Hh-signal-
ing inhibitor, cyclopamine, is enriched in Veratrum cali-
fornicum. This plant when consumed by pregnant sheep 
resulted in a midline differentiation defect in offspring 
[13–17]. Hh-signaling activation can lead to reprogram-
ming by driving the expression of Bmi1, and the endog-
enous Smoothened activator, oxysterol, can facilitate 
reprogramming [8].
Similar to other core development related pathways, 
deregulated Hh-signaling due to the mutation or overex-
pression of pathway components and/or pathway ligand 
induces a variety types of cancers including basal cell car-
cinoma, medulloblastoma, bladder cancer, breast cancer, 
cervical cancer, liver cancer, colon cancer, prostate can-
cer, gastric cancer, pancreas cancer, head and neck can-
cer, lymphoma and non-small cell lung cancer [18–32]. 
The pivotal role of Hh-signaling in cancer development 
makes Hh-signaling an attractive target for drug develop-
ment [33–36]. For example, the FDA in 2012 approved 
GDC-0449, an Hh pathway inhibitor targeting Smooth-
ened for basal cell carcinoma treatment [33, 37, 38].
Hh signaling pathway is controlled by membrane 
proteins Patched (Ptch) and Smo. When there is no 
ligand bound to Ptch, Ptch inhibits Smo and keeps the 
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downstream pathway inactivated. When Ptch binds 
to Hh ligand, the inhibition of Ptch on Smo is relieved 
and the Hh-signaling pathway is activated. One of the 
broadly accepted mechanisms of Hh-signaling target 
genes response is through the binding of Gli family tran-
scription factors to Gli-binding sites in the regulatory 
sequence of Hh regulated genes.
Esrrb belongs to the nuclear receptor family [39–41]. 
It is important in early embryo development as genomic 
knock out of Esrrb is embryonic lethal due to the pla-
centa deformation resulted from early differentiation 
of trophoblast stem cells [42]. Recent research showed 
that Esrrb was found to be a core reprogramming fac-
tor in inducing pluripotent stem cells (iPSC). C-myc and 
klf4 of Yamanaka factors (Oct4, Sox2, Klf4, c-Myc) can 
be replaced by Esrrb [43–46]. Esrrb was also reported 
to drive Sox2 transcription to induce reprogramming in 
a single cell reprogramming system, revealing its cen-
tral role in differentiation [47]. In addition, Esrrb was 
found to play an important role in tumorigenesis in both 
in vitro and in vivo studies. It is down-regulated in pros-
tate cancer and re-expression of Esrrb in prostate cancer 
cells inhibited cancer cell proliferation through tumor 
suppressor Cdkn1a/p21 induction [48, 49].
Esrrb has been reported to be constitutively active in 
the absence of a ligand and this is supported by the evi-
dence that Esrrg, which shares over 80  % of its Ligand 
Binding Domain with Esrrb, has a transcriptional active 
conformation similar to E2-activated Estrogen Receptor 
[50–53]. Another explanation for this endogenous activ-
ity is that Esrrb binds to an unknown endogenous ligand. 
The Esrrb endogenous ligand hypothesis is supported by 
a report that culturing the cells with charcoal-stripped 
serum-containing medium can eliminate the transcrip-
tional activity of Esrrb on SFRE/ERRE [54].
Knocking down Esrrb in mouse embryonic stem cells 
was shown to affect the transcription of several Hh-sign-
aling pathway related genes, including Gli2 and several 
Wnt family members, indicating Esrrb can potentially 
regulate Hh driven gene expression [55].
Although Gli transcription factors are relatively well 
known for transmitting Hh-signaling to target genes, 
other factors mediating the Hh-signaling activity are 
not well studied. For example, Dner, Fbn2, Hsd11b1 and 
Brak are Hh responsive genes in fetal prostate, but over-
expression of Gli1 or Gli2 cannot affect the transcription 
of these 4 genes. However, the expression of active Smo 
significantly increased the mRNA concentration of these 
genes [56], indicating there is at least one other mecha-
nism accounting for the Hh-signaling target gene tran-
scription regulation.
Due to the importance of both Esrrb and Hh-signaling 
in development and tumorigenesis, we hypothesized that 
Esrrb can regulate Hh-mediated transcription regula-
tion and can serve as a regulator of Hh-signaling target 
genes. By employing mRNA profiling, we emphasized on 
the discovery of Esrrb-regulated Hh-signaling pathway-
targeted genes and we report 109 genes that differentially 
respond to Hh-signaling activation with Esrrb present.
Results
Establishment of model cell lines
With the purpose of exploring whether Esrrb can regulate 
Hh-signaling targeted genes, we require a Hh-responsive 
cell line. NIH3T3 cells are commonly used as Hh-respon-
sive cell line. Additionally, this cell line does not express 
Esrrb, making it a good model that provides clean back-
ground of Esrrb. To make the NIH3T3 cells Esrrb posi-
tive, we stably transfected Esrrb into NIH3T3 cells. The 
control vector transfected NIH3T3 cells (NIH3T3-pc3.1) 
have no Esrrb expressed as mentioned before. In con-
trast, NIH3T3 cells transfected with Esrrb expression 
vector (NIH3T3-Esrrb) have significantly increased Esrrb 
protein concentration (Fig.  1a). Compared to HEK293 
cells, which have endogenous Esrrb expressed but lack 
of detectable Hh-signaling response, the concentration 
of overexpressed Esrrb in NIH3T3 cells attained a physi-
ological relevant concentration (Fig. 1a).
Hedgehog signaling and Esrrb regulated genes
To comprehensively characterize Hh-signaling driving 
mRNA changes in our system, we performed RNA-Seq 
analysis on the mRNA isolated from NIH3T3-pc3.1 cells 
treated with vehicle control or 1 % Hh ligand conditioned 
medium (Hh-CM). Hedgehog signaling pathway activation 
after Hh-CM treatment was confirmed by significantly 
increased concentration of Gli1 by westernblot (Fig.  1b). 
After the Hh-CM treatment, we distinguished a total of 
339 (245 up-regulated, 94 down-regulated) altered mRNAs 
(Figs. 2, 3a, Additional file 1: Table S3). We collected pub-
lished Hh-signaling target gene sets generated by activat-
ing the Hh-signaling pathway or Gli transcription factor 
overexpression/knock-down in different model cell lines or 
tissues as Ref. [56–63]. For all of the non-redundant 1348 
Fig. 1 Characterization of model cell line. a Expression of Esrrb is 
confirmed by Western blot. Two replicates of Esrrb transfected cells 
showed successful expression of Esrrb protein and b 1 % Hh-CM 
treated NIH3T3-pc3.1 showed increased concentration of Gli1 protein
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genes from previous reports, we found 48 genes (enrich-
ment p value = 1.68e–06) that overlapped and another 291 
new Hh-signaling responsive genes (Fig. 2).
We also surveyed the gene expression in NIH3T3-
Esrrb cells. 171 genes were differentially expressed by 
Esrrb expression (Additional file 1: Table S2; Additional 
file 2: Figure S1). We compared Esrrb-regulated genes to 
Hh-induced genes, and found there are 12 genes, Fabp4, 
Phex, Ccl5, Tagln, Aldh1a7, Lmod1, Cesla, Igf1, Mafb, 
Steap4, Pfkfb3 and Hlf, which are up-regulated or down-
regulated by either Hh ligand or Esrrb expression (Addi-
tional file 2: Figures S1,  S2, #1–8). The presence of these 
genes implies that Hh-signaling and Esrrb have func-
tional overlaps in the regulation of these genes.
Hh‑signaling regulated genes in the presence of Esrrb
Next we treated NIH3T3-Esrrb cells with Hh-CM to test 
gene response. Esrrb expression with Hh-CM treatment 
led to the largest amount of altered mRNAs (Fig.  3a). 
Supportively, spearman ranking correlation of all mRNA 
profiles in four different conditions showed that each 
condition generates different mRNA profiles, and cor-
relation between Hh-signaling pathway stimulation in 
the presence of Esrrb expression and the no Esrrb no 
Hh stimulation control resulted in the lowest correlation 
coefficient in all pairwise comparisons (Fig. 3b).
Theoretically, mRNA profiling from four different con-
ditions (Control, Hh-CM, Esrrb, Esrrb + CM) generates 
six different differentially expression pairwise compari-
sons. Since the comparison “Hh-CM vs. Esrrb” lacks of 
apparent interest, only five comparisons were left (refer 
to “Methods”). Every gene can be differentially expressed 
or not in any of the five given comparisons, therefore the 
comparison results can contain 25 different possibilities 
for each gene.
We defined a group of genes as “Hh differentially 
response genes” as they response to Hh-CM when there 
is no Esrrb, while when Esrrb is expressed, their response 
to Hh-CM is further enhanced, depressed or lost. These 
genes will indicate Esrrb can regulate Hh-signaling path-
way activity. To find Hh differentially response genes, we 
used computer assisted gene sorting (“Methods”, Addi-
tional file 2: Figure S2). The genes that fit our definition of 
“Hh differentially response” were found in groups #1, #2, 
#3, #4, #5, #9, #10 and #14 (Additional file 1: Table S3). 
Using the indicated filters of fold change and RPKM 
value described in “Methods”, we classified 109 genes 
that differentially respond to Hh-CM treatment when 
Esrrb is expressed (Additional file 2: Figure S2). We con-
firmed the concentration of 15 highly expressed mRNAs 
(saa3, prl2c3, dpt, sfrp2, pdcd4, smoc2, igf1, stmn1, top2a, 
tubb4b, hp, hoxd8, igfbp4, hsd11b1, ogn) by qPCR. Pear-
son correlation coefficients between RNA-Seq and qPCR 
are at least 0.9 (Additional file  2: Figure  S4). Among 
tested mRNAs, we found that when Esrrb express-
ing cells are treated with Hh-CM, Sfrp2 (secreted friz-
zle related protein 2), Saa3 (serum amyloid A3), Prl2c3 
(prolactin 2A3), Stmn1 (stathmin1), Hp (haptoglobin), 
Hoxd8 (homeoboxD8), Tubb4b (tubulin beta 4B), Top2a 
(topoisomerase II alpha) and Dpt (dermatopontin) had 
different mRNA concentrations compared to Hh-CM 
treatment in cells without Esrrb. These differences are 
more likely due to a proportional additive effect of Esrrb 
expression on altered baseline expression of the mRNAs 
(Fig. 4a). In contrast, Igf1 (Insulin-like growth factor 1), 
Pdcd4 (programmed cell death 4) and Smoc2 (SPARC 
related calcium binding 2) lost their response to Hh 
stimuli when Esrrb was present (Fig.  4b). On the other 
hand, Hsd11b1 (hydoxysteroid 11 beta dehydrogenase 
1), Igfbp4 (insulin-like growth factor binding protein 4) 
and Ogn (osteoglycin) responded to Hh-CM better when 
Esrrb was expressed (Fig. 4b).
Discussion
We distinguished 339 Hh-signaling altered mRNAs, 
among which are 48 known Hh-signaling target genes 
and 291 newly discovered targets (Fig.  3a, Additional 
file 1: Table S2). Most importantly, we characterized 109 
genes that behave differently in response to Hh ligand in 
the presence versus the absence of Esrrb expression. This 
group of genes contains genes as Igf1, which respond to 
Hh ligand treatment in the absence of Esrrb, but when 
Esrrb is expressed, Hh ligand treatment cannot modify 
its transcription (Fig.  4b); genes as Hoxd8, which has 
differential expression in response to Hh stimulation 
Fig. 2 Hh-signaling target genes. Previously reported Hh-signaling 
targeted genes were retrieved, only the genes that have more than 
twofold change are kept. The Hh responsive genes from our assay 
were compared to the reported genes. Venn diagram shows known 
Hh-signaling genes with the Hh-signaling responsive genes from 
our study were compared. The 48 overlapped genes (enrichment 
score = 1.68e−06) contain 41 Hh-signaling up-regulated genes, and 
7 down-regulated genes
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when Esrrb is expressed, though this different response 
comes from the effect of Esrrb on basal level mRNA 
concentration (Fig.  4a). We also observed genes like 
Hsd11b1 (Hh-CM vs. control: 21-fold; Esrrb +  Hh-CM 
vs. Esrrb: 59 fold), Igfbp4 (Hh-CM vs. control: 3.4-fold; 
Esrrb + Hh-CM vs. Esrrb: 7.6 fold), and Ogn (Hh-CM vs. 
control: 57 % inhibition; Esrrb + Hh-CM vs. Esrrb, 83 % 
inhibition), which indicate that Esrrb and the Hh-signal-
ing pathway synergistically regulate these genes (Fig. 4b). 
These results demonstrated that Esrrb is capable of inter-
acting with Hh-signaling pathway and potentially regu-
late Hh-signaling downstream targets.
In the canonical Hh-signaling pathway model, the acti-
vation of Smo transmits the Hh signal to Gli transcrip-
tion factor through the activation and inactivation of 
several pathway components including Fused [30] and 
Suppressor of Fused (SuFu). However, the evidence that 
the transcription of Hsd11b1, Fbn2 and Brak respond to 
active Smo transfection, but not Gli1 or Gli2 overexpres-
sion, indicates that Smo activation has a Gli-independent 
function in regulating gene expression [56]. In support 
of this hypothesis, we listed all the transcription factors; 
chromatin remodeling factors and transcription co-fac-
tors that response to Hh-signaling activation for future 
reference (Additional file 2: Figure S2).
There are 21 genes (group #25) that respond to Hh-
signaling but only when Esrrb is present (Log2FC > 1 or 
Log2FC <−1) (Additional file  2: Figure  S5). 20 of them 
are up-regulated and 1 is down-regulated. This indicates 
Esrrb has the ability to expand the transcription regula-
tion of the Hh-signaling pathway.
Additionally, we found cortisol-cortisone converting 
enzyme Hsd11b1 is correlated to Hh-signaling activation 
from several reports in several model systems includ-
ing fetal prostate, prostate cancer and embryonic fibro-
blast cell lines [56, 64], indicating cortisone converted 
from cortisol by Hsd11b1 may account for part of the Hh 
response gene profile. Surprisingly, we found the classic 
Glucocorticoid Receptor (GR) target gene, Mt2, along 
with 3 Hh-signaling activation inhibits all other genes 
that have Glucocorticoid Response Elements in their pro-
moter regions, Aldh1a7, Ankrd1 and Ism1 are repressed 
in response to Hh treatment (Additional file  2: Fig-
ure S6). Although Esrrb does not change the expression 
a b
Fig. 3 Pair-wise comparisons for differentially expressed genes within Control, Hedgehog treatment, Esrrb expression and Esrrb expression 
plus Hedgehog treatment. a Scatter plot of gene expression values in different conditions. 0.001 is added to the RPKM value of each transcript 
and resulted RPKM + 0.001 values are log2 transformed. For each plot, each point (Xcondition1, Ycondition2) on the plot represents the log2 
(RPKM + 0.001) of the gene in indicated conditions. If a certain gene passed the different expression test, that gene is highlighted by blue color, 
otherwise is red colored. All pair-wise comparisons are plotted, except Hedgehog vs. Esrrb, which lacks biological meaning and b Spearman Ranking 
Correlation was used to analyze the similarity of mRNA profiles in control, Hh-signaling activation, Esrrb expression and Hh-signaling activation 
with Esrrb expression. Spearman ranking correlation coefficient was calculated and Hierarchical clustered. Correlation coefficient is color coded as 
indicated in the figure
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- 1:100 Hh-CM + 1:100 Hh-CM
a
b
Fig. 4 Quantitative PCR validation of the top 15 Hedgehog signaling differentially responsive mRNAs. Hh-signaling differentially responsive genes 
as determined by RNAseq were confirmed by qPCR after NIH3T3-pc3.1 and NIH3T3-Esrrb cells are treated with Hh-CM. Each mRNA concentration 
is normalized to housekeeping gene GAPDH, and further normalized to that ratio in NIH3T3-pc3.1. Y-axis represents relative fold change to no 
Esrrb expressed no Hh-CM treated control. a Esrrb altered the Hh-CM treatment response, due to a proportional additive effect from Esrrb expres-
sion. When Esrrb is expressed, the genetic response to Hh is different than the condition without Esrrb expressed, Asterisk means p < 0.01 and b 
genes respond to Hedgehog signaling better when Esrrb is expressed as well as genes losing Hh response when Esrrb is expressed, Asterisk means 
p < 0.01 Number sign means “not statistically significant”
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of Hsd11b1, Hh treatment with Esrrb expression further 
increased the mRNA concentration of Hsd11b1, accom-
panied by statistically significant alterations in concen-
trations of Mt2, Aldh1a7, Ankrd1 and Ism1 (Additional 
file  2: Figure  S6). Our discovery strongly supports the 
idea that metabolite(s) downstream of Smo can also be 
mediators of Hh-signaling responses. Interestingly, GR 
overexpression and the activation of its target genes are 
strongly associated with anti-androgen treatment in pros-
tate cancer therapy. GR target genes overlap with those of 
the Androgen Receptor and have been determined to be 
involved in antiandrogen treatment enzalutamide resist-
ance [65]. Inhibiting GR can restore enzalutamide sen-
sitivity. Esrrb’s activity in increasing Hsd11b1 indirectly 
represses GR activity by potentially lowering the GR 
ligand cortisol, and thus activating Esrrb may lead to bet-
ter response of antiandrogen treatment and eliminate or 
postpone the resistance.
Conclusions
Our data provided useful reference marker genes for 
both Hh-signaling and Esrrb function. In addition, we 
also showed that Esrrb has a role in the regulation of Hh-
signaling driven genes. The mechanism of Hh-signaling 
was also expanded and a new layer of regulation of the 
Hh pathway through Esrrb was revealed, which may lead 
to improved treatments in Hh-signaling driven diseases.
Methods
Conditional medium
Sonic Hedgehog conditioned medium (Hh-CM) is col-
lected from cultured HEK293 cells carrying Sonic 
Hedgehog (Shh) N-terminus transgene, which was a 
gift from Dr. Phillip Beachy’s lab. Briefly, the Shh stable-
transfected cells were maintained in Dulbecco’s Modified 
Eagal Medium (DMEM, Invitrogen, Grand Island, NY, 
USA) with 10 % Fetal Bovine Serum (FBS) until conflu-
ent, the medium was switched to DMEM with 0.2 % FBS 
after 2 days. The medium enriched with Shh-N terminus 
was collected 24 h later, and was filtered through 0.22 μM 
filter, and stored in −80° freezer [32].
Cell lines and Expression vectors
All cell lines used in this study were obtained commer-
cially, and we did not conduct any animal work to obtain 
them. Paracrine Hh-responsive mouse embryonic fibro-
blast cells NIH3T3 were obtained from American Type 
Culture Collection (ATCC, Cat. No. CRL-1658). NIH3T3 
cells are cultured in DMEM supplement with 10 % New-
born Calf Serum (NBCS). The cells were transfected 
with pcDNA3.1 (Zeo+) empty vector (Promega, Madi-
son, WI) as control, or pcDNA3.1 (Zeo+)-Esrrb expres-
sion vector using Fugene HD (Promega, Madison, WI), 
and were further selected by supplementing 150 μg/ml 
Zeocine (Invitrogen, Grand Island, NY) to the culture 
medium for 3 weeks. Two independent transfections 
were performed and established cells from each trans-
fection were pooled together. Cells were cultured until 
confluent, and are treated with 1:100 diluted Hh-CM 
for 48  h, in phenol-red free DMEM supplement with 
5 % NBCS. The Hh-CM treatment was controlled by the 
same dilution of medium cultured HEK293 cells that do 
not express Shh N-terminus transgene.
Reverse transcriptase PCR and real time PCR
Total RNA was isolated and purified from two biologi-
cal replicates of NIH3T3-pc3.1 and NIH3T3-Esrrb using 
RNeasy kit (Qiagen, Venlo, Netherlands) respectively. 
1000 ng of total RNA was used to create cDNA libraries 
using Superscript III Reverse Transciptase (Invitrogen, 
Grand Island, NY) with random primers and oligodT. 
Quantitative PCR (qPCR) assays were carried out using 
SYBR GREEN iQ supermix (BioRad, Herculus, CA, USA) 
on ABI7500 system (Applied Biosytems, Foster City, CA, 
USA). Each qPCR assay was repeated 3 times. qPCR con-
dition: 95°, 30 s; 60°, 40 s; 72°, 40 s. Primer sequences:
GAPDH (NM_008084), forward primer: AGCCTCGT 
CCCGTAGACAAAAT, reverse primer: CCGTGAGT 
GGAGTCATACTGGA;
Patched (NM_008957), forward primer: CTCTGGAG 
CAGATTTCCAAGG, reverse primer: TGCCGCAG 
TTCTTTTGAATG;
Gli1 (NM_010296), forward primer: GGAAGTCCT 
ATTCACGCCTTGA, reverse primer: CAACCTTCT 
TGCTCACACATGTAAG;
Igf1 (NM_001111274), forward primer: TGAGTGG 
CTTCCCTTGGGGG, reverse primer: AGGTGTTGT 
TTTGTGGGTGGGGT;
Smoc2 (NM_022315), forward primer: GGAAGGAG 
CAGGGAAAGCAGATGAT, reverse primer: TGGGCT 
GCTTGGCTTCCTCAAG;
Pdcd4 (NM_001168491), forward primer: GGACACT 
CCTAGGGCACCGC, reverse primer: TCCGCTTCC 
CGCCTTTGGAC;
Stmn1 (NM_019641), forward primer: TCGGACCGA 
GCAGGGCTTTC, reverse primer: CCGAGGGCT 
GAGAATCAGCTCAA;
Hp (NM_017370), forward primer: GAGGCAGTGTG 
TGGGAAGCCC, reverse primer: GGTCAGCAGCCAC 
TGGTCACT;
Ogn (NM_008760), forward primer: ACGACCTGGA 
ATCTGTGCCTCC, reverse primer: TTGGATTGCCCT 
CCAGGCGA;
Hoxd8 (NM_008276), forward primer: TTCCCTG 
GATGAGACCACAAGCAGC, reverse primer: GTCTC 
TCCGTGAGGGCCAGAGT
Page 7 of 10Lu et al. BMC Molecular Biol  (2015) 16:19 
Dpt (NM_019759), forward primer: TCAGTGCTGGA 
TCGTGAGTGGC, reverse primer: ACTGGCGATC 
CCTTTCCACTGC;
Top2a (NM_011623), forward primer: CCCAGGGAA 
GCTCCATGTCGG, reverse primer: GGTTCCCTTTGG 
CGCAGCTC;
Igfbp4 (NM_010517), forward primer: GATCGTGG 
GGACACCTCGGG, reverse primer: GCGGGGTGAC 
ACTGTTTGGGG;
Tubb4b (NM_146116), forward primer: TGTTGGCA 
GAGCGTCGGTTGT, reverse primer: CGCTGATTA 
CCTCCCAGAACTTGGC;
Hsd11b1 (NM_001044751): forward primer: CTGCCT 
GCCTGGGAGGTTGT, reverse primer: TCCCTGGAG 
CATTTCTGGTCTGAAC;
Sfrp2 (NM_009144): forward primer: GGCCACAGA 
GGAAGCTCCCAA, reverse primer: TCGGACACGCCG 
TTCAGCTT;
Saa3 (NM_011315): forward primer: ACAGCCAAAGA 
TGGGTCCAGTTCA, reverse primer: ACAGCCTCTCT 
GGCATCGCTGA;
Prl2c3 (NM_011118): forward primer: AGCCAGGC 
TCACACACTATGCAG, reverse primer: CCCGTTCCG 
GACTGCGTTGA;
Immunoblot
600,000 cells were plated in 6-well-plate. After 24  h 
growth in medium containing 10 % NBCS, the cells were 
treated with 1 % Hh-CM in phenol-red free DMEM with 
5  % NBCS for 48  h. Cells were lysed by protein sample 
buffer (BioRad, Herculus, CA, USA) and boiled for 5 min 
at 95°. 20 μg of total protein was loaded on 12  % SDS-
PAGE gel. Electrophoresis was then performed. The 
proteins were then transferred to nitrocellulose mem-
brane. The membrane was block by Phosphate buffered 
saline (PBS) with 0.05 % Tween 20, 0.015 g/ml dry milk 
and 0.015 g/ml bovine serum albumin (BSA). The mem-
brane was then incubated with 1:2000 diluted monoclo-
nal anti-Gli1 mouse IgG (Cell signaling, Beverly, MA, 
Cat.No: L42B10), 1:2000 diluted monoclonal anti-Esrrb 
mouse IgG (R&D system, Cat. No: PP-H6705-00) and 
1:2000 diluted polyclonal anti-GPADH rabbit IgG (Santa 
Cruz, Dallas, TX, Cat. No: sc-25777) overnight, washed, 
incubated with secondary antibodies diluted in PBS 
with 0.01  g/ml BSA. The chemoluminescence was gen-
erated by west-Dura (Promega, Madison, WI, USA) and 
recorded by X-ray film (Fisher Scientific, Pittsburg, PA, 
USA).
Deep sequencing and data analysis
2500  ng total RNA from 2 biological replicates of each 
culture condition were extracted and purified, and then 
used to generate sequencing cDNA library using TruSeq 
Stranded mRNA Sample Preparation kits (Illumina, San 
Diego, CA). Eight samples were pooled in one lane and 
each sample was ligated to one specific barcoded aligner. 
cDNA libraries quality was determined by University of 
Missouri DNA core. Deep sequencing was performed 
by University of Missouri DNA core using Illumina 
HiSeq  2000. Around 18 million reads were generated 
in.fastq format for each sample (raw data and data repos-
itory accession number will be available upon manuscript 
acceptance). The sequencing reads were trimmed and fil-
tered using FASTX-Toolkit (http://hannonlab.cshl.edu/
fastx_toolkit), and mapped to UCSC mm9 genome using 
Bowtie2 and TopHat2 [66, 67]. Genome mapping results 
were submitted to Galaxy public server (galaxy.psu.edu) 
for gene expression value quantification. Gene expression 
value is represented as Reads Per Kilobase of transcript 
per Million mapped reads (RPKM) by Cufflink refer-
ence genome guided transcript assembly. Gene models 
from different experiment were merged together by Cuff-
merge and all pair-wise comparisons of relative mRNA 
concentrations were analyzed by Cuffdiff. Differentially 
expressed genes are determined by False Discovery 
Rate adjusted p-value (q-value < 0.05), Log2Fold Change 
(Log2FC ≥ 1 or ≤−1).
Gene sorting and Hh differentially response genes 
characterization
Five pairwise comparisons, (1) control vs. Hh-CM, 
(2) control vs. Esrrb, (3) control vs. Esrrb  +  Hh-CM, 
(4) Hh-CM vs. Esrrb  +  Hh-CM, (5) Esrrb vs. 
Esrrb  +  Hh-CM, but not Esrrb versus Hh-CM treat-
ment, were made through differentially expressed gene 
analysis Cuffdiff, and test results are stored for each tran-
script [Yes (Y): q  <  0.05, statistically significantly differ-
ent; or No (N): q  >  0.05, not significant]. Each gene is 
then sorted into 1 of the 32 groups based on each test 
result using an in-house R script (available upon request, 
Additional file  2: Figure  S1). For each of the 16 groups 
of Hh responsive genes (control vs. Hh-CM, q < 0.05), a 
logic determination is made to filter out the groups that 
have pairwise comparison results against themselves 
(group #6, #7, #8, #12, #13, #15, #16) or groups with no 
real world interest (#11). Genes in the rest groups (#1, 
#2, #3, #4, #5, #9, #10 and #14) are for further data fil-
ter and analysis. For the genes that passed the Hh-CM 
vs. Esrrb  +  Hh-CM test, we further filtered out genes 
that have −0.5  <  [(RPKM(Esrrb  +  Hh-CM) − RPK-
MHh-CM)/RPKMHh-CM]  <  0.5, −0.5  <  [(RPKM(Hh-
CM) − RPKMcontrol)/RPKMcontrol]  <  0.5, and 
−5  <  [RPKM(Esrrb  +  Hh-CM) − RPKMHh-CM]  <  5. 
For the genes that do not pass the Hh-CM vs. 
Esrrb + Hh-CM, the genes that have −0.5 < [(RPKM(Hh-
CM) − RPKM(control))/RPKMcontrol]  <  0.5, 
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[(RPKM(Esrrb  +  Hh-CM) − RPKMHh-CM)/RPK-
MHh-CM]  >  0.1 or <−0.1, −0.5  <  [(RPKM(Esrrb) − 
RPKM(control))/RPKMcontrol]  <  0.5 are filtered out. 
All genes that have passed the above tests are classified 
as Hh differentially response genes, and they respond to 
Hh-CM treatment differentially in the conditions with or 
without Esrrb expression.
Gene ontology and KEGG pathway analysis
DAVID bioinformatics source 6.7 is used for gene ontol-
ogy (GO) analysis and KEGG pathway analysis [68, 69]. 
The gene names from certain pairwise comparison result 
were submitted to DAVID server (http://david.abcc.ncif-
crf.gov) and GO analysis were performed for biological 
process (BP). Minimum counts were set as default value 
(two counts) and maximum EASE score (p value) was 
set to 0.05. Same parameter was used for KEGG pathway 
analysis.
Hh‑signaling related genes enrichment analysis
Previous published Hh-signaling related gene sets 
generated by deep sequencing or microarray were 
retrieved (Refer to Additional file 1: Table S1 for spe-
cific experiment conditions and Hh-signaling targeted 
gene set descriptions). Briefly, only mRNAs altered 
more than twofold are included. Up-regulated and 
down-regulated mRNAs are sub-grouped and mRNA 
associated sequence identifications are all converted 
to gene symbols. Hh altered mRNAs in our gene set 
are compared to the previous reported mRNAs, 
and enrichment p value is calculated as previously 
described [70].
Statistical analysis
Spearman Ranking Correlation is analyzed using R (ver-
sion 3.0.2). RPKM value for each mRNA from both 
biological replicate in each condition is collected for cor-
relation. The resulted pairwise correlation coefficients 
are stored in a matrix and Hierarchical clustering is cre-
ated by R/Bioconductor (version 2.13) package Heat-
plus 2. Each Spearman correlation coefficient is color 
transformed for data visualization. qPCR experiments 
were repeated 3 times on two biological replicates. qPCR 
results were analyzed using t-test (p  <  0.01). Hh differ-
entially response mRNA concentrations measured by 
RNAseq and qPCR are correlated using Pearson method 
in R. Briefly, for each tested mRNA, qPCR tested rela-
tive concentration is normalized by the concentration 
of internal control GAPDH, and further normalized to 
control condition. RNA-seq generated RPKM values are 
normalized to the value from control. Correlation is then 
performed between the above two sets of normalized 
expression values.
Availability of supporting data
The data sets supporting the results of this article are 
available in the NCBI-GEO repository, GSE71209 
h t t p : / / w w w. n c b i . n l m . n i h . g o v / g e o / q u e r y / a c c .
cgi?acc=GSE71209.
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